GB1299198A - Pyrrolobenzodiazepinone derivatives - Google Patents
Pyrrolobenzodiazepinone derivativesInfo
- Publication number
- GB1299198A GB1299198A GB62863/69A GB6286369A GB1299198A GB 1299198 A GB1299198 A GB 1299198A GB 62863/69 A GB62863/69 A GB 62863/69A GB 6286369 A GB6286369 A GB 6286369A GB 1299198 A GB1299198 A GB 1299198A
- Authority
- GB
- United Kingdom
- Prior art keywords
- compound
- formula
- aryl
- alkoxy
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1299198 Antibiotic pyrrolobenzodiazepinone derivatives FUJISAWA PHARMACEUTICAL CO Ltd 24 Dec 1969 [30 Dec 1968 26 June 1969] 62863/69 Heading C2A Novel pyrrolobenzodiazepinone derivatives having the Formula (I) wherein R 1 is H, C 1 -C 6 alkyl, C 1 -C 6 alkylcarbonyl, aryl-C 1 -C 6 alkylcarbonyl, or arylcarbonyl; Y is -N=CH- or -NH-CHR- and R is C 1 -C 6 alkoxy, aryl-C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, aryl-C 1 -C 6 alkylthio, or di(C 1 -C 6 alkyl)amino, are prepared from a new compound of unknown chemical structure obtained by aerobically cultivating Streptomyces achromogenes var. tomaymyceticus (ATCC 21353) by treating said compound as follows: (a) reacting with an alcohol of formula R<SP>1</SP>H to give a compound of Formula (A) wherein R<SP>1</SP> is C 1 to C 6 alkoxy; (b) dissolving the compound (A) in a non-alcoholic organic solvent to convert it into a compound of Formula (B) (c) reacting the compound (A) or the compound (B) with an acylating agent to form a compound of Formula (C) wherein R<SP>1</SP> 1 is C 1 -C 6 alkylcarbonyl, aryl- C 1 -C 6 alkylcarbonyl or arylcarbonyl, and Y is -N=CH- or -NH-CHR<SP>1</SP> and R<SP>1</SP> is as defined in (a) above; (d) reacting the compound (A) or the compound (B) with an alkylating agent to give a compound of Formula (D) wherein R<SP>11</SP> 1 is C 1 -C 6 alkyl and Y is -N = CH- or -NH-CHR<SP>1</SP> and R<SP>1</SP> is as defined in (a) above; (e) dissolving the compound (C) in which Y is -NH-CHR<SP>1</SP>- in a non-alcoholic organic solvent to convert it into a compound of Formula (E) wherein R<SP>1</SP> 1 is as defined in (c) above; (f) reacting the compound (B) or (E), or the compound (C) or (D) in which Y is -N=CH-, with an alcohol, thioalcohol or dialkylamine to give a compound of Formula (I) wherein R is C 1 -C 6 alkoxy, aryl-C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, aryl-C 1 -C 6 alkylthio, or di(C 1 -C 6 alkyl)- amino. The initial fermentation is carried out under conventional conditions for the culture of a Streptomycete. The said new compound may be subjected to the aforesaid treatment either in the fermentation broth (preferably filtered) or after isolation. Such isolation may be by extraction with a water-immiscible solvent (e.g. ethyl acetate or chloroform) or by adsorption on e.g. diatomaceous earth, activated carbon or alumina, silica gel or silicic acid, followed by elution with a polar organic solvent or aqueous such solvent. The compound may be purified by fractional chromatography and isolated by evaporation of the solvent or precipitation by adding a non-solvent. When an alcohol is used in the preparative procedure, the product is the alcohol-reaction compound (A) instead of the said new compound. The inventive compounds (I) variously have activity against gram-positive and gram-negative bacteria, phages, viruses and tumours. Pharmaceutical compositions having such activity comprise a compound of Formula I together with a physiologically acceptable carrier or diluent; they may be in forms suitable for injection or oral administration.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP8368 | 1968-12-30 | ||
JP44050780A JPS4843755B1 (en) | 1969-06-26 | 1969-06-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
GB1299198A true GB1299198A (en) | 1972-12-06 |
Family
ID=26332992
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB62863/69A Expired GB1299198A (en) | 1968-12-30 | 1969-12-24 | Pyrrolobenzodiazepinone derivatives |
Country Status (6)
Country | Link |
---|---|
ES (1) | ES375013A1 (en) |
FI (1) | FI46259C (en) |
GB (1) | GB1299198A (en) |
IE (1) | IE33906B1 (en) |
IL (1) | IL33558A (en) |
RO (1) | RO55813A (en) |
Cited By (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0101924A1 (en) * | 1982-07-26 | 1984-03-07 | Bristol-Myers Company | Antitumor antibiotics |
WO2000012508A2 (en) * | 1998-08-27 | 2000-03-09 | Spirogen Limited | Pyrrolbenzodiazepines |
US6608192B1 (en) | 1998-08-27 | 2003-08-19 | Spirogen Limited | Collections of compounds |
US6747144B1 (en) | 1998-08-27 | 2004-06-08 | Spirogen Limited | Collections of compounds |
US6909006B1 (en) | 1999-08-27 | 2005-06-21 | Spirogen Limited | Cyclopropylindole derivatives |
US7407951B2 (en) | 2002-11-14 | 2008-08-05 | Spirogen Limited | Pyrrolobenzodiazepines |
US7429658B2 (en) | 2003-09-11 | 2008-09-30 | Spirogen Limited | Synthesis of protected pyrrolobenzodiazepines |
US7528126B2 (en) | 2004-03-09 | 2009-05-05 | Spirogen Limited | Pyrrolobenzodiazepines |
US7557099B2 (en) | 2004-03-01 | 2009-07-07 | Spirogen Limited | Pyrrolobenzodiazepines as key intermediates in the synthesis of dimeric cytotoxic pyrrolobenzodiazepines |
US7741319B2 (en) | 2004-03-01 | 2010-06-22 | Spirogen Limited | 11-hydroxy-5h-pyrrolo[2,1-c][1,4] benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepines |
US8592576B2 (en) | 2008-10-17 | 2013-11-26 | Spirogen Sarl | Unsymmetrical pyrrolobenzodiazepine-dimers for treatment of proliferative diseases |
US8697688B2 (en) | 2010-04-15 | 2014-04-15 | Seattle Genetics Inc. | Pyrrolobenzodiazepines used to treat proliferative diseases |
US8829184B2 (en) | 2010-04-15 | 2014-09-09 | Spirogen Sarl | Intermediates useful for the synthesis of pyrrolobenzodiazepines |
US20140286970A1 (en) | 2011-10-14 | 2014-09-25 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
US9102704B2 (en) | 2011-10-14 | 2015-08-11 | Spirogen Sarl | Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines |
US9242013B2 (en) | 2010-04-15 | 2016-01-26 | Seattle Genetics Inc. | Targeted pyrrolobenzodiazapine conjugates |
US9388187B2 (en) | 2011-10-14 | 2016-07-12 | Medimmune Limited | Pyrrolobenzodiazepines |
US9387259B2 (en) | 2011-10-14 | 2016-07-12 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
US9399073B2 (en) | 2011-10-14 | 2016-07-26 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines |
US9399641B2 (en) | 2011-09-20 | 2016-07-26 | Medimmune Limited | Pyrrolobenzodiazepines as unsymmetrical dimeric PBD compounds for inclusion in targeted conjugates |
US9415117B2 (en) | 2012-10-12 | 2016-08-16 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US9745303B2 (en) | 2012-10-12 | 2017-08-29 | Medimmune Limited | Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation |
US9919056B2 (en) | 2012-10-12 | 2018-03-20 | Adc Therapeutics S.A. | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates |
US9931414B2 (en) | 2012-10-12 | 2018-04-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US9931415B2 (en) | 2012-10-12 | 2018-04-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US9950078B2 (en) | 2013-10-11 | 2018-04-24 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US9956298B2 (en) | 2013-10-11 | 2018-05-01 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US9956299B2 (en) | 2013-10-11 | 2018-05-01 | Medimmune Limited | Pyrrolobenzodiazepine—antibody conjugates |
US10010624B2 (en) | 2013-10-11 | 2018-07-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US10335497B2 (en) | 2012-10-12 | 2019-07-02 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US10392393B2 (en) | 2016-01-26 | 2019-08-27 | Medimmune Limited | Pyrrolobenzodiazepines |
US10420777B2 (en) | 2014-09-12 | 2019-09-24 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US10543279B2 (en) | 2016-04-29 | 2020-01-28 | Medimmune Limited | Pyrrolobenzodiazepine conjugates and their use for the treatment of cancer |
US10544223B2 (en) | 2017-04-20 | 2020-01-28 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
US10695439B2 (en) | 2016-02-10 | 2020-06-30 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
US10695433B2 (en) | 2012-10-12 | 2020-06-30 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US10736903B2 (en) | 2012-10-12 | 2020-08-11 | Medimmune Limited | Pyrrolobenzodiazepine-anti-PSMA antibody conjugates |
US10751346B2 (en) | 2012-10-12 | 2020-08-25 | Medimmune Limited | Pyrrolobenzodiazepine—anti-PSMA antibody conjugates |
US10780096B2 (en) | 2014-11-25 | 2020-09-22 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
US10799595B2 (en) | 2016-10-14 | 2020-10-13 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
US11059893B2 (en) | 2015-04-15 | 2021-07-13 | Bergenbio Asa | Humanized anti-AXL antibodies |
US11160872B2 (en) | 2017-02-08 | 2021-11-02 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
US11318211B2 (en) | 2017-06-14 | 2022-05-03 | Adc Therapeutics Sa | Dosage regimes for the administration of an anti-CD19 ADC |
US11352324B2 (en) | 2018-03-01 | 2022-06-07 | Medimmune Limited | Methods |
US11370801B2 (en) | 2017-04-18 | 2022-06-28 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
US11517626B2 (en) | 2016-02-10 | 2022-12-06 | Medimmune Limited | Pyrrolobenzodiazepine antibody conjugates |
US11524969B2 (en) | 2018-04-12 | 2022-12-13 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof as antitumour agents |
US11612665B2 (en) | 2017-02-08 | 2023-03-28 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US11649250B2 (en) | 2017-08-18 | 2023-05-16 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
US11702473B2 (en) | 2015-04-15 | 2023-07-18 | Medimmune Limited | Site-specific antibody-drug conjugates |
-
1969
- 1969-12-17 IL IL33558A patent/IL33558A/en unknown
- 1969-12-22 FI FI693710A patent/FI46259C/en active
- 1969-12-24 GB GB62863/69A patent/GB1299198A/en not_active Expired
- 1969-12-29 ES ES375013A patent/ES375013A1/en not_active Expired
- 1969-12-30 IE IE1726/69A patent/IE33906B1/en unknown
- 1969-12-30 RO RO62025A patent/RO55813A/ro unknown
Cited By (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0101924A1 (en) * | 1982-07-26 | 1984-03-07 | Bristol-Myers Company | Antitumor antibiotics |
JP4824165B2 (en) * | 1998-08-27 | 2011-11-30 | スパイロジエン・リミテツド | Pyrrolobenzodiazepines |
US7067511B2 (en) | 1998-08-27 | 2006-06-27 | Spirogen Limited | Pyrrolobenzodiazepines |
EP1193270A2 (en) * | 1998-08-27 | 2002-04-03 | Spirogen Limited | Pyrrolobenzodiazepines |
EP1193270A3 (en) * | 1998-08-27 | 2002-04-17 | Spirogen Limited | Pyrrolobenzodiazepines |
US6608192B1 (en) | 1998-08-27 | 2003-08-19 | Spirogen Limited | Collections of compounds |
EP1413582A1 (en) * | 1998-08-27 | 2004-04-28 | Spirogen Limited | Dimeric pyrrolobenzodiazepines |
US6747144B1 (en) | 1998-08-27 | 2004-06-08 | Spirogen Limited | Collections of compounds |
US7704924B2 (en) | 1998-08-27 | 2010-04-27 | Spirogen Limited | Library of compounds comprising pyrrolobenzodiazepine moieties |
US7049311B1 (en) | 1998-08-27 | 2006-05-23 | Spirogen Limited | Pyrrolbenzodiazepines |
WO2000012508A2 (en) * | 1998-08-27 | 2000-03-09 | Spirogen Limited | Pyrrolbenzodiazepines |
US7265105B2 (en) | 1998-08-27 | 2007-09-04 | Spirogen Limited | Pyrrolobenzodiazepines |
WO2000012508A3 (en) * | 1998-08-27 | 2000-09-21 | Univ Portsmouth | Pyrrolbenzodiazepines |
US6909006B1 (en) | 1999-08-27 | 2005-06-21 | Spirogen Limited | Cyclopropylindole derivatives |
US7407951B2 (en) | 2002-11-14 | 2008-08-05 | Spirogen Limited | Pyrrolobenzodiazepines |
US7429658B2 (en) | 2003-09-11 | 2008-09-30 | Spirogen Limited | Synthesis of protected pyrrolobenzodiazepines |
US7557099B2 (en) | 2004-03-01 | 2009-07-07 | Spirogen Limited | Pyrrolobenzodiazepines as key intermediates in the synthesis of dimeric cytotoxic pyrrolobenzodiazepines |
US7741319B2 (en) | 2004-03-01 | 2010-06-22 | Spirogen Limited | 11-hydroxy-5h-pyrrolo[2,1-c][1,4] benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepines |
US7528126B2 (en) | 2004-03-09 | 2009-05-05 | Spirogen Limited | Pyrrolobenzodiazepines |
US8592576B2 (en) | 2008-10-17 | 2013-11-26 | Spirogen Sarl | Unsymmetrical pyrrolobenzodiazepine-dimers for treatment of proliferative diseases |
US9624227B2 (en) | 2008-10-17 | 2017-04-18 | Medimmune Limited | Unsymmetrical pyrrolobenzodiazepine-dimers for treatment of proliferative diseases |
US8940733B2 (en) | 2008-10-17 | 2015-01-27 | Spirogen Sarl | Unsymmetrical pyrrolobenzodiazepine-dimers for treatment of proliferative diseases |
US8697688B2 (en) | 2010-04-15 | 2014-04-15 | Seattle Genetics Inc. | Pyrrolobenzodiazepines used to treat proliferative diseases |
US9732084B2 (en) | 2010-04-15 | 2017-08-15 | Medimmune Limited | Pyrrolobenzodiazepines used to treat proliferative diseases |
US9592240B2 (en) | 2010-04-15 | 2017-03-14 | Seattle Genetics Inc. | Targeted pyrrolobenzodiazapine conjugates |
US9242013B2 (en) | 2010-04-15 | 2016-01-26 | Seattle Genetics Inc. | Targeted pyrrolobenzodiazapine conjugates |
US8829184B2 (en) | 2010-04-15 | 2014-09-09 | Spirogen Sarl | Intermediates useful for the synthesis of pyrrolobenzodiazepines |
US10561739B2 (en) | 2010-04-15 | 2020-02-18 | Seattle Genetics Inc. | Targeted pyrrolobenzodiazapine conjugates |
US9399641B2 (en) | 2011-09-20 | 2016-07-26 | Medimmune Limited | Pyrrolobenzodiazepines as unsymmetrical dimeric PBD compounds for inclusion in targeted conjugates |
US9399073B2 (en) | 2011-10-14 | 2016-07-26 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines |
US9387259B2 (en) | 2011-10-14 | 2016-07-12 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
US9526798B2 (en) | 2011-10-14 | 2016-12-27 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
US9102704B2 (en) | 2011-10-14 | 2015-08-11 | Spirogen Sarl | Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines |
US20140286970A1 (en) | 2011-10-14 | 2014-09-25 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
US9707301B2 (en) | 2011-10-14 | 2017-07-18 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
US9713647B2 (en) | 2011-10-14 | 2017-07-25 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
US9388187B2 (en) | 2011-10-14 | 2016-07-12 | Medimmune Limited | Pyrrolobenzodiazepines |
US10328084B2 (en) | 2011-10-14 | 2019-06-25 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
US10329352B2 (en) | 2011-10-14 | 2019-06-25 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
US9931415B2 (en) | 2012-10-12 | 2018-04-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US10799596B2 (en) | 2012-10-12 | 2020-10-13 | Adc Therapeutics S.A. | Pyrrolobenzodiazepine-antibody conjugates |
US11690918B2 (en) | 2012-10-12 | 2023-07-04 | Medimmune Limited | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates |
US11701430B2 (en) | 2012-10-12 | 2023-07-18 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US11771775B2 (en) | 2012-10-12 | 2023-10-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US10994023B2 (en) | 2012-10-12 | 2021-05-04 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US9919056B2 (en) | 2012-10-12 | 2018-03-20 | Adc Therapeutics S.A. | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates |
US9745303B2 (en) | 2012-10-12 | 2017-08-29 | Medimmune Limited | Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation |
US10335497B2 (en) | 2012-10-12 | 2019-07-02 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US11779650B2 (en) | 2012-10-12 | 2023-10-10 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US10780181B2 (en) | 2012-10-12 | 2020-09-22 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US9931414B2 (en) | 2012-10-12 | 2018-04-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US12121590B2 (en) | 2012-10-12 | 2024-10-22 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US9415117B2 (en) | 2012-10-12 | 2016-08-16 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US10646584B2 (en) | 2012-10-12 | 2020-05-12 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US10751346B2 (en) | 2012-10-12 | 2020-08-25 | Medimmune Limited | Pyrrolobenzodiazepine—anti-PSMA antibody conjugates |
US10695433B2 (en) | 2012-10-12 | 2020-06-30 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US10722594B2 (en) | 2012-10-12 | 2020-07-28 | Adc Therapeutics S.A. | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates |
US10736903B2 (en) | 2012-10-12 | 2020-08-11 | Medimmune Limited | Pyrrolobenzodiazepine-anti-PSMA antibody conjugates |
US10010624B2 (en) | 2013-10-11 | 2018-07-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US9956299B2 (en) | 2013-10-11 | 2018-05-01 | Medimmune Limited | Pyrrolobenzodiazepine—antibody conjugates |
US9956298B2 (en) | 2013-10-11 | 2018-05-01 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US9950078B2 (en) | 2013-10-11 | 2018-04-24 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US10420777B2 (en) | 2014-09-12 | 2019-09-24 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US10780096B2 (en) | 2014-11-25 | 2020-09-22 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
US11059893B2 (en) | 2015-04-15 | 2021-07-13 | Bergenbio Asa | Humanized anti-AXL antibodies |
US11702473B2 (en) | 2015-04-15 | 2023-07-18 | Medimmune Limited | Site-specific antibody-drug conjugates |
US10392393B2 (en) | 2016-01-26 | 2019-08-27 | Medimmune Limited | Pyrrolobenzodiazepines |
US10695439B2 (en) | 2016-02-10 | 2020-06-30 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
US11517626B2 (en) | 2016-02-10 | 2022-12-06 | Medimmune Limited | Pyrrolobenzodiazepine antibody conjugates |
US10543279B2 (en) | 2016-04-29 | 2020-01-28 | Medimmune Limited | Pyrrolobenzodiazepine conjugates and their use for the treatment of cancer |
US10799595B2 (en) | 2016-10-14 | 2020-10-13 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
US11612665B2 (en) | 2017-02-08 | 2023-03-28 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US11160872B2 (en) | 2017-02-08 | 2021-11-02 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
US11813335B2 (en) | 2017-02-08 | 2023-11-14 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US11370801B2 (en) | 2017-04-18 | 2022-06-28 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
US10544223B2 (en) | 2017-04-20 | 2020-01-28 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
US11318211B2 (en) | 2017-06-14 | 2022-05-03 | Adc Therapeutics Sa | Dosage regimes for the administration of an anti-CD19 ADC |
US11938192B2 (en) | 2017-06-14 | 2024-03-26 | Medimmune Limited | Dosage regimes for the administration of an anti-CD19 ADC |
US11649250B2 (en) | 2017-08-18 | 2023-05-16 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
US11352324B2 (en) | 2018-03-01 | 2022-06-07 | Medimmune Limited | Methods |
US11524969B2 (en) | 2018-04-12 | 2022-12-13 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof as antitumour agents |
Also Published As
Publication number | Publication date |
---|---|
FI46259C (en) | 1973-02-12 |
ES375013A1 (en) | 1972-03-01 |
RO55813A (en) | 1974-02-01 |
IE33906L (en) | 1970-06-30 |
IL33558A (en) | 1973-10-25 |
IE33906B1 (en) | 1974-12-11 |
IL33558A0 (en) | 1970-04-20 |
FI46259B (en) | 1972-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB1299198A (en) | Pyrrolobenzodiazepinone derivatives | |
Hanson et al. | An antiphage agent isolated from Aspergillus sp | |
McInerney et al. | Biologically active metabolites from Xenorhabdus spp., Part 2. Benzopyran-1-one derivatives with gastroprotective activity | |
Ohkuma et al. | BBM-928, a new antitumor antibiotic complex I. Production, isolation, characterization and antitumor activity | |
Hochstein et al. | 2-Acetyl-2-decarboxamidoöxytetracycline | |
Argoudelis et al. | MICROBIAL TRANSFORMATION OF ANTIBIOTICS. III CONVERSION OF CLINDAMYCIN TO 1'-DEMETHYLCLINDAMYCIN AND CLINDAMYCIN SULFOXIDE BY STREPTOMYCES SPECIES | |
Argoudelis et al. | Paulomycins A and B isolation and characterization | |
US4359583A (en) | Antibiotics TM-531 B and TM-531 C | |
US4425430A (en) | Process for production of antibiotics and novel antibiotics produced thereby | |
Brodasky et al. | Steffimycin B, a new member of the steffimycin family: isolation and characterization | |
Keller-Juslen et al. | Septamycin, a polyether antibiotic taxonomy, fermentation, isolation and characterization | |
Hamill et al. | Macrocin, a new antibiotic, and lactenocin, an active degradation product | |
GB1303842A (en) | ||
US4209511A (en) | Aminoglycoside antibiotics and process for production thereof | |
Furumai et al. | STUDIES ON THE BIOSYNTHESIS OF BASIC 16-MEMBERED MACROLIDE ANTIBIOTICS, PLATENOMYCINS. II PRODUCTION, ISOLATION AND STRUCTURES OF 3-O-PROPIONYL-5-OMYCAMINOSYL PLATENOLIDES I AND II, 9-DEHYDRO DEMYCAROSYL PLATENOMYCIN AND DEMYCAROSYL PLATENOMYCIN | |
IE37892B1 (en) | Antibiotic a-2315 and process for preparation thereof | |
GB1226494A (en) | ||
GB1292010A (en) | A new antibiotic, its production and its use | |
AU652280B2 (en) | Antibiotic LL-E19020 alpha1 | |
Ando et al. | A NEW ANTIBIOTIC, 1-(p-HYDROXYPHENYL)-2, 3-DIISOCYANO-4-(p-METHOXYPHENYL)-BUTA-1, 3-DIENE. I ISOLATION AND BIOLOGICAL PROPERTIES (STUDIES ON ANTIVIRAL AND ANTITUMOR ANTIBIOTICS. II) | |
US4003902A (en) | Naphthyridinomycin antibiotics | |
IL42700A (en) | Antibiotic g-52 and method for the production thereof | |
JPS6253157B2 (en) | ||
Argoudelis et al. | Directed biosynthesis of new celestosaminide-antibiotics by Streptomyces caelestis | |
SU1344248A3 (en) | Method of producing macromide antibiotic |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PS | Patent sealed [section 19, patents act 1949] | ||
PLNP | Patent lapsed through nonpayment of renewal fees |